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Aims: The aim of this systematic review was to explore and evaluate the efficacy of
interventions to reduce the prevalence of look-alike, sound-alike (LASA) medication
name errors.
Methods: We conducted a systematic review of the literature, searching PubMed,
EMBASE, Scopus and Web of Science up to December 2016, and re-ran the search
in February 2020 for later results. We included studies of interventions to reduce
LASA errors and included randomized controlled trials, controlled before-and-after
studies, and interrupted time series. Details were registered in Prospero (ID:
CRD42016048198).
Results: We identified six studies that fulfilled our inclusion criteria. All
were conducted in laboratories. Given the diversity in the included studies, we
did not conduct a meta-analysis and instead report the findings narratively.
The only intervention explored in RCTs was capitalization of selected letters
(“Tall Man”), for which we found limited efficacy and no consensus.
Conclusions: Tall Man lettering is a marginally effective intervention to
reduce LASA errors, with a number of caveats. We suggest that Tall Man
gives rise to a “quasi-placebo effect”, whereby a user derives more benefit
from Tall Man lettering if they are aware of its purpose. Keywords:
(on scholar one).
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1 | INTRODUCTION
Medication errors are a leading cause of patient harm in the
UK. Between July 2018 and June 2019 they accounted for 10.7% of
incidents (206 485 medication incidents out of a total of 1 936 812
incidents), 66 deaths and 159 instances of “severe harm”.1 When
medications have names that look or sound alike, and/or have similar
packaging, they may be confused, leading to medication errors. These
look-alike, sound-alike (LASA) errors are a type of wrong drug error
under the 5Rs framework.2 LASA errors can occur at any point on the
treatment pathway during prescribing, dispensing or administration of
medicines. They may result in overdosing, under-dosing or inappropri-
ate dosing, representing a significant threat to patient safety.3–6
This systematic review explores interventions to reduce the prev-
alence of LASA errors due to similar-looking or -sounding names. It is
based on the study protocol published in PROSPERO7 and is accom-
panied by a review article looking at drivers and solutions to the prob-
lem of LASA errors.6
Review protocol: PROSPERO, published in 2016 (http://www.crd.york.ac.uk/PROSPERO/
display_record.php?ID=CRD42016048198).
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1.1 | Previous reviews
When our initial literature search was carried out in 2016, no system-
atic reviews of LASA error interventions had been published and only
one literature review of LASA errors existed.6 That review focused on
the prevalence of LASA errors, searching for (look AND [sound/exp
OR sound] AND alike AND [drug/exp OR drug]) and reviewing
14 papers from PubMed and EMBASE. It included interventions such
as Tall Man lettering, but there was no meta-analysis. Other papers
nonsystematically reviewed the literature, such as Emmerton and
Rizk,3 and included interviews with key industry experts, such as phar-
macists and psycholinguists.
A systematic literature review8 was subsequently published in
2018 on strategies to avoid look-alike labelling errors. The authors of
this review8 looked only at “original studies” published in English
involving healthcare professionals or “consumers”, with no restric-
tions on study design. Although this review and our own were carried
out concurrently, we view them as complementary. Our inclusion
criteria comprised all types of LASA error, including spoken errors, in
four languages. We have included studies on healthcare professionals
and only study designs that used a comparator as a basis of analysis.
Our primary objective was to systematically identify and evaluate
comparative studies of interventions, delivered in any healthcare
setting, that aimed to reduce the rate of LASA errors.
2 | METHODS
We reviewed interventions used in any type of (sub)population. The
search strategy criteria for inclusion and exclusion, and data extraction
are described below.
2.1 | Primary outcome measures
1. Any measure of effect on LASA error rates, or relative measures of
LASA error rates (increased, the same or decreased) derived from
any intervention, compared with “no intervention” or usual care or
placebo.
2. Any marker used to test an intervention, such as readability, which
is used to test the efficacy of Tall Man lettering.
2.2 | Literature search and screening
We conducted searches for full-length peer-reviewed articles in elec-
tronic databases, hand-searching reference lists in included articles
and hand-searching references in systematic reviews and literature
reviews. We searched the following electronic databases in the
autumn of 2016: MEDLINE (via PubMed), EMBASE, Scopus and Web
of Science. Search strategies are given in the appendices. Owing to
variations in LASA terminology, reference lists of the results were
hand-searched for further relevant results. The inclusion criteria are
given in Table 1. The search was re-run on Medline only on
14 February 2020 and results were screened by RB. Results from the
new search are combined with those from the first search in the
PRISMA diagram in Figure 1.
A PubMed search for (LASA AND [drug OR name OR error])
revealed that the acronym LASA was first used in any PubMed
source in 2011 by Kovacic and Chambers,9 and there were a few
earlier papers using “sound-alike” or “look-alike”, such as
Dembicki10 in 1967. LASA is thus a recently coined term, and
much of the literature pertaining to LASA errors uses alternative
discourse, such as “name confusion” or “similar drug names”, and
TABLE 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
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even other acronyms such as SALA (sound-alike, look-alike)9 or
LASARA (look-alike, sound-alike, read-alike).11 The search strategy
in this review therefore accounted for inconsistency in terminology
in this relatively recent field.
2.3 | Inclusion and exclusion criteria
2.4 | Data extraction and assessment of study
quality
The two reviewers independently extracted the name of the first
author, year of publication, study type, participants' professions or
education focus, types of intervention, types of outcome measure,
study aims and study type. GRADE criteria were used to assess the
quality of the evidence. If there was any disagreement, the data were
rechecked, with resolution via discussion or by inviting a third author
to give a final decision.
3 | RESULTS
3.1 | Outcomes of the search
The outcomes of the search strategy, by stage, are shown in the
PRISMA diagram (Figure 1). The first (main) literature search identi-
fied 922 research papers from four databases, which were then
screened by RB, AW and SJ. A total of six papers were selected for
data extraction from both searches, but one12 was subsequently
removed because the data were unavailable (Rachel Bryan
communicated via email with lead author Ramzi Shawahna in Octo-
ber 2016; he was unable to access the data needed for inclusion in
the review). The six studies13–18 are described in Table 2, with a
description of excluded studies in Table 3. The screening process is
shown in the PRISMA flow diagram in Figure 1, combining results
from both searches.
3.1.1 | Differences in terminology usage
There is surprising variation in terminology relating to LASA experi-
ments and measures, and some harmonization of terms would aid
communication and discussion in the field.
Three studies13,14,17 distinguished between two types of errors:
one in which the person mistakenly identifies a LASA pair as the same
name (type 1 in Table 4) and one in which the same name is mistak-
enly identified as two different names (type 2 in Table 4). Filik13
explored findings for both of these outcomes, but only deemed the
first type (her “target absent”) as relevant. Accuracy in identifying
“target present” shows that the name is easy to remember and recog-
nize, while “target absent” requires the participant to distinguish the
LASA names. An error means that they incorrectly identify them as
being identical and reveals a potential to confuse them in practice. Or
and Wang15 only looked at how accurately two different names in a
LASA pair were distinguished, not how accurately two names were
recognized as being identical. Because the participant responded only
when they detected a change, there was no mechanism for them to
mistakenly identify two names in a LASA pair as a single name.
Schell14 explored two error rates. First, errors of omission, wherein
two distinct names are misidentified as the same (Filik et al's13 “target
present” and Liu et al's “correct rejections and false alarms”17), and
second, errors of commission, wherein a single name is misidentified
F IGURE 1 PRISMA flow diagram:
green indicates studies added and red
indicates studies removed
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TABLE 4 Types of LASA error
Type Action 13 14 15
1 Stating that two different names in a LASA pair are the same
name
Target present error Error of omission False alarm
2 Stating that two identical names are different Target absent error Error of commission Miss
LASA, look-alike, sound-alike.
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as two distinct names (Filik et al's “target absent” and Liu et al's “hits
and misses”17). Only outcomes measuring the accuracy of dis-
tinguishing between two names in a LASA pair were deemed relevant
in this review, as this could lead to a LASA confusion error between
two medications. However, mistakenly identifying a single name as
two distinct names suggests that the name may be difficult to remem-
ber and recognize, and, as Schell14 points out, hints at the likelihood
of false error alerting and is a good measure to be used when an inter-
vention may heighten a user's sensitivity to error identification by
drawing attention to particular names. All authors referred to P values
when reporting their findings and took P < .05 as “statistically
significant”.
3.2 | Analysis of studies
All six studies were undertaken in laboratories. The number of partici-
pants was 11-127. Six studies were selected13–18 after all the papers
had been scrutinized under the inclusion/exclusion criteria. A sum-
mary of outcome measurements is given in Table 5. All six studies
assessed the efficacy of Tall Man lettering in emphasizing differences
between similar (LASA) names, using a change in typography as an
intervention to reduce the rate of drug name confusion errors. The
accuracy of drug name differentiation was an outcome measure in
four studies14–17 and measurement of the error rate of drug name dif-
ferentiation was an outcome in the other two.11,16 Four of the six
studies13–15,17 used some form of “same vs different” procedure to
test a participant's ability to distinguish two names. In the other two
studies, DeHenau et al16 used a change detection test procedure and
Wang and Or18 used a visual search and selection procedure. Mistak-
enly identifying that two different LASA names (eg hydroxyzine and
hydralazine from Filik et al13) are the same reveals a potential for con-
fusion in clinical practice; this type of error is more likely to reach
patients, as the difference between the names has been overlooked
and thus the medicines could be substituted. Therefore, figures for
that type of error are given below and compared with counterparts
from the other two studies.
In four of the six studies, Tall Man lettering statistically signifi-
cantly increased the accuracy or reduced the error rate of drug name
differentiation. Two studies, Schell14 and Wang and Or18 found no
significant support for Tall Man lettering. In the case of Schell,14 this
is most probably because of the small sample size (n = 11). In the case
of Wang and Or,18 they hypothesized that the nonsignificance may
have arisen because participants performed too few drug search trials
(160). It was impossible to combine the findings from the four studies
given that each study used different test procedures and outcomes,
and since other potential confounders, such as the drug names, their
orthographic similarity, test environments and conditions, and the
levels of education and experience of the participants, were unstated
or not accounted for in the analysis.
Filik et al13 found that Tall Man lettering led to a small but signifi-
cant reduction in name differentiation errors compared with no inter-
vention (using correct or orthodox typography “the natural case”, ie,
lowercase for generic names and initial capitalization for brand
names).
Schell14 reported that name recognition was not significantly
affected by the various typographic adaptations, with the caveat that
the sample size (n = 11) was too small, resulting in a lack of statistical
power.
Or et al15 confirmed that Tall Man lettering can reduce errors in
differentiation, but added that the most effective form of typographic
adaptation was Tall Man + bold, presumably because it highlights
salient letters and reduces the difficulty of visual search and
detection.
DeHenau et al16 found that Tall Man lettering can reduce errors
in differentiation and that this effect was compounded by the user's
particular knowledge of the names: when a user was familiar with only
one of the names in a pair (rather than neither or both), Tall Man let-
ters had a significant positive effect on accuracy because the familiar
name will be recognizable more readily to the user and so the addi-
tional typographic change should amplify this effect. However, it can
be surmised from this that if the user is familiar with both names the
benefit is cancelled out.
Findings from Liu et al17 support Tall Man plus boldface lettering
as a method of increasing accuracy in drug name differentiation, but
they did not test Tall Man lettering alone, so it may be that combined
text enhancement is a stronger intervention. They found that for
nurses this effect was only seen with short exposure times, indicating
that Tall Man lettering is most beneficial in the immediate stages of
visual search because the highlighted letters attract attention.
Wang and Or18 found that Tall Man lettering increased the error
rate, although the effect was not significant. They found limited sup-
port for boldface plus contrast and suggested that greater efficacy
may lie in combinations of text enhancements, which is supported by
Liu et al.17
3.2.1 | Concerns about Tall Man lettering
The interplay between Tall Man lettering and response time is compli-
cated: Filik et al13 reported a small but possibly clinically significant
increase in response time (39.6 ms for lowercase letters, 42.9 ms for
Tall Man letters, P < .001), whereas DeHenau et al16 found that Tall
Man lettering reduced response times. Wang and Or18 found that Tall
Man lettering increased “perceived mental effort” and response times,
but the effect was not clinically or statistically significant (all P values
of independent variables >0.05). Schell,14 looking at errors of commis-
sion (when the user misidentifies a single name as two distinct names),
found that Tall Man letters can increase response bias, which will lead
to more false alarms, whereby the user identifies an error where there
is none. This could be because a change in typography indicates that
the name is at risk of confusion. Of course, a more liberal response
bias will necessarily lead to capture of actual errors.
DeHenau et al16 found a difference in magnitude in the benefit of
Tall Man letters between their participant groups, with healthcare
professionals deriving more benefit. This could be the “quasi-placebo













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































BRYAN ET AL. 9
effect” of Tall Man letters: when users are aware of the method they
are primed to be more wary of look-alike names and so they will be
less likely to make a look-alike name confusion error.13 Conversely,
Filik et al13 found a greater reduction in error rate in laypersons from
Tall Man lettering, so the effect is unclear.
3.2.2 | Limitations of the studies
The numbers of study participants were low, ranging from 1114 to
127.12 Only large differences would have yielded statistically signif-
icant findings. Future studies would benefit from larger test
cohorts, although this may not be feasible when restricting partici-
pants to healthcare professionals and in-person testing. Using eye-
tracking technology can also complement experiments in drug
name selection and recognition13,18 by providing researchers with
more information on the user's selection process. Furthermore, the
transferability of laboratory-based studies to the real world is
unclear.
The full versions of two papers were unavailable34,38 and a fur-
ther paper was removed because the data were not accessible.12
These papers were not included in the analysis.
There is no standard method for applying Tall Man lettering to
names. Filik et al13 used a bespoke method in their study, dubbed
CD3, and Schell14 noted that Tall Man lettering methods vary consid-
erably. Future research efforts should work to build consensus on a
standardized method for Tall Man lettering and also consider how to
apply it in trios of names with asymmetric similarities (such as car-
boplatin, cisplatin and carboprost), and in electronic prescribing soft-
ware, where medicines are arranged alphabetically and/or by
condition, eg salbutamol/salmeterol.
3.3 | Risk of bias
The risk of bias varied between studies, as outlined in Table 6.
None of the four studies described the participant selection or
recruitment process, so there is a high risk of volunteer bias. Per-
formance bias is deemed high in all four studies. Because Tall Man
lettering or other typographic adaptations are visual changes to the
presentation of names, there is no way to blind participants in a
trial.
3.4 | Quality of evidence assessment using the
GRADE criteria
Using GRADE, the quality of the body of evidence explored in this
review was overall low. We considered each of the GRADE criteria
(risk of bias, directness of evidence, consistency and precision of
results, risk of publication bias, magnitude of the effect, dose-
response gradient and influence of residual plausible confounding; see
Table 7).
4 | DISCUSSION
From 1721 titles and abstracts read, we explored six studies, all
looking at the capacity of Tall Man lettering to emphasize differences
between similar names and thus to reduce the rate of drug name con-
fusion errors. Four of the six studies suggested that Tall Man lettering
can increase the accuracy of drug name differentiation
(or alternatively reduce errors), compared with standard lowercase let-
tering. The effect of Tall Man lettering on response time is not clear
from these studies. However, the indirectness of the measures used
and the varying absolute differences seen reduced the quality of the
evidence.
4.1 | Limitations of the review
We carried out this review in four databases, but did not search grey
literature, white/green papers or e-theses. References in each full
paper screened were hand-searched for additional relevant studies,
but we found none, suggesting that our initial search was effective.
Although we opened the search to four languages (English, Italian,
Spanish and Russian), all the search terms were in English and we
therefore identified only papers whose abstracts and keywords had
been translated into English from the source language. This assumes
that correct English terminology and vernacular was used, which may
not be the case when machine translation is used. Consequently, we
identified only English studies. It is possible that we missed results in
other languages not included in the search strategy or that we missed
papers that did not translate their abstract into English. A lack of
papers in languages other than English does not mean that LASA
errors are an Anglophone phenomenon or that only Anglophone
countries report medication errors, but simply that English language
literature is easier to locate (eg, the European Medicines Agency's
publications are in English).
4.2 | Generalizability
From such small numbers and laboratory settings, it is difficult to gen-
eralize to real-world wider populations working under intense pres-
sure in safety-critical environments. Participants in the same vs
different drug name differentiation tasks reviewed here were
healthcare professionals, whom the authors presume to have high
levels of literacy and knowledge of concerns about patient harms, and
perhaps even knowledge of interventions such as Tall Man lettering.
The findings cannot be automatically extrapolated to lay people or
student nurses/doctors.
In this review, varying levels of bias restricted the quality of the
evidence. All the experiments described relied on volunteers and so
volunteer selection bias must be taken into account. Participants were
all healthcare professionals, but the studies included in this review did
not detail the recruitment processes or the first language of the
respondents, and so it may be that those who volunteered had an
10 BRYAN ET AL.
interest in drug name confusion, patient safety, typography, LASA
errors or other relevant topics, or were highly motivated practitioners.
This could lead to dissonance between their performance and the
likely performance of the “average” healthcare professional.
The Hawthorne effect, in which knowledge of being observed
causes an individual to modify some aspect of their behaviour,52 must
not be discounted. During the experiments it is likely that participants
had increased sensitivity to differences between medication names,
compared with everyday practice, and so error rates may have been
underreported. Similarly, the Rosenthal effect, in which expectations
affect performance,53 is relevant. It is possible that healthcare profes-
sionals felt higher expectations to perform well in medication name
differentiation, but this is difficult to determine because the included
studies did not describe how fully participants were informed of the
purpose of the experiments.
Larmene-Beld et al8 cited a recent study conducted in a hospital
environment54 exploring 1 676 700 hospitalizations in which Tall Man
lettering had no beneficial effect. That study was excluded from this
review as it was a before and after observational study and not a ran-
domized controlled trial. They examined paediatric pharmacy data
from 42 children's hospitals over 9 years to explore the occurrence of
errors involving 12 particular LASA name pairs. Among 1 676 700
hospitalizations, implementation of Tall Man lettering was not associ-
ated with a reduction in the LASA error rate.
4.3 | Comparison with other reviews
Hand-searching and cascade-reading of the field revealed two litera-
ture reviews focused on interventions for LASA errors. Neither
TABLE 6 Risk of bias assessments
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conducted meta-analyses because of the heterogeneity of the
included studies.
Larmene-Beld et al8 included 16 studies in their systematic
review (with no restriction on study design or type of participant), of
which 11 evaluated the use of Tall Man lettering and seven had statis-
tically significant findings. Six of these showed that participants made
fewer errors when the drug names contained Tall Man lettering than
when the drug names were displayed in lowercase. They cited Schell14
as showing an increase in overall error rate using Tall Man letters over
lowercase (taking as the only significant outcome measure overall
error rate in Study 1 with nonhealthcare professionals). In this review
we took outcome measures relating to Study 2 with healthcare
professionals, which found a null effect (but this was nonsignificant,
all P values >.05). They similarly noted that the interaction between
Tall Man letters and response time is mixed and seems to depend on
an individual's knowledge of Tall Man letters.
Ciociano and Bagnasco55 included 14 studies in their narrative
review, two of which looked at the effect of Tall Man letters. The
first23 found no effect of Tall Man on error rate in a same vs different
task (laboratory outcome), but the participants were not healthcare
professionals. This aligns with the findings from this review regarding
the Tall Man quasi-placebo effect, in that when users are aware of the
intervention and its purpose, they are more likely to derive an
outcome from it. Healthcare professionals are presumably more aware
of medication errors and interventions such as Tall Man letters. The
other included paper56 described how Tall Man letters were
integrated into a hospital network. The authors describe a number of
interventions and emphasize the importance of policymaking in
reducing errors. Policymaking is crucial both in creating international
regulations to limit confusability of names when they are chosen by
pharmaceutical companies and nomenclature bodies, and in best use
of technological approaches such as Tall Man lettering.
4.4 | Wider context
Under Reason's theory of error mitigation, a system approach
recognizes that humans are fallible and that errors occur through
latent conditions in the system (in this case, healthcare).57 The
presence of LASA names is a latent condition: it increases the risk of
error. The system approach mitigates the risk of error by putting up
multiple safeguards, which block the pathway of an error and prevent
it from reaching the end user. We have shown that as one such
safeguard, Tall Man lettering, has unclear effectiveness.
Or and Wang15 looked at the interplay between orthographic
similarity and various methods of typographic adaptation. They found
a statistically significant increase in accuracy with a corresponding
reduction in similarity, ie, names are harder to differentiate when they
are very similar to each other. This is hardly surprising, but the authors
pointed out that the effect of orthographic similarity was sustained in
all the various typographic adaptations. This means that there is a
ceiling of efficacy and in certain high-risk situations (with highly similar
names) the risk of confusion cannot be mitigated by typography
alone.
The effect of Tall Man lettering on response time is unclear: in
one study it reduced response time16 and in another increased it.13
Larmene-Beld et al8 similarly found a mixed response in their included
studies. It may be that response time is mediated by how frequently a
particular medication name is used by the individual practitioner:
names for commonly prescribed medications will be better known and
thus may take less time to recognize. Medication names are specialist
items in a language and some are used very infrequently. Frequency
of prescription is positively correlated with accuracy in the visual per-
ception of medication names31: lesser used names are more likely to
be confused or misunderstood.
Linguistically, Tall Man lettering involves a mixture of cases, nor-
mally with lowercase at the beginning and end of the word and a
block of capitalization in the middle, eg, hydrALAzine. Case has histor-
ically been disregarded in linguistics as having an impact on reading
speed or visual perception based upon an influential experiment on
the effect of AlTeRnAtInG cAsE.58 However, recent reading experi-
ments have found a lowercase advantage in reading,59 in which case
Tall Man letters could reduce the readability of names. It may also be
that blocks of uppercase letters in a Tall Man name are treated as
acronyms, which can slow down perception by increasing the number
of times users' eyes fixate on them.60
TABLE 7 GRADE criteria assessment
Criterion Assessment
Risk of bias Unclear
Directness Very low (laboratory only)
Consistency and precision of
results
Low; wide range of effect, from null to 9% improvement
Risk of publication bias Uncertain; small negative studies are often not published; these studies were not registered in research
databases
Magnitude of effect Small
Dose-response gradient Not explored in any studies
Residual plausible confounding Unknown, but likely to be low in artificial laboratory settings; not reported
Other bias Volunteer selection bias
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5 | CONCLUSIONS
Based on the criteria outlined in the search and screening strategy for
this systematic review, the evidence suggests that Tall Man lettering
is a marginally effective intervention to reduce LASA drug name con-
fusion errors in laboratory settings. Its effectiveness may be mediated
by additional typography, such as emboldening,15 whether or not a
user is familiar with one more of the names16 and orthographic simi-
larity.15 We have identified a “Tall Man quasi-placebo effect”, wherein
a user derives more benefit from Tall Man lettering if they are aware
of its purpose.16
The paucity of evidence for the efficacy and effectiveness of Tall
Man lettering suggests that it should be used with caution and as one
part of a larger arsenal of medication error-reduction strategies.
5.1 | Implications for practice
Tall Man lettering is no panacea or substitute for adequate education.
Policymakers should be mindful that there is no evidence from clinical
practice that Tall Man lettering reduces clinically significant errors and
take care when advising the use of Tall Man lettering until the evi-
dence base matures.
5.2 | Implications for research
Trials with much larger samples need to be undertaken and, as far as
possible, interventions should be evaluated in clinical practice. More
detailed exploration of LASA errors using linguistic theory is needed
to understand the problem and propose amelioration strategies based
on more than one aspect of linguistics.
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APPENDIX
PubMed search strategy
Terms were searched in title and abstract ([tiab] on PubMed) to
retrieve results that are both focused (title) and closely related
(abstract) to LASA errors. First several broad parameters that may co-
occur with LASA error discourse, such as the method of delivery (eg,
dispensing), the type of incident (eg, near miss), medication or a syno-
nym (eg, drug), the type of medication name (eg, generic), aspects such
as packaging or labelling, and interventions such as font adaptation
and automated alerts (eg, Tall Man lettering) were defined. These
were then combined with Boolean operator AND to form an array of
search terms. This array was combined with variants of LASA to find
more specific papers, and the search was finally narrowed by
searching for only those papers fulfilling the preceding conditions and
with relevant MeSH terms as a major subject heading([majr] on
PubMed).
First search run 16 December 2016 with open dates;
second search run 14 February 2020 for publications after
16 December 2016 (adding 22016/12:2020/02 [edat]” to search
strategy)
KEY: [ti] = Title field only; .[tiab] = Title & Abstract fields;
MESH = Medical Subject Headings No Limits Appli-
ed Search run: 2015 12 16: RESULTS = 4168 #1pre-
scri*[tiab] OR drug administ*[tiab] OR dispens*[tiab] OR
pharmacist*[tiab] OR drug*[tiab] OR medicine*[tiab] OR
medication*[tiab] OR pharmaceutical*[tiab] OR
pharmacotherapeutic agent*[tiab] OR medicinal product*
[tiab] OR "Drug Therapy"[Mesh ] OR "Prescriptions"[Mesh]
OR "Pharmaceutical Preparations"[Mesh] #2Error*[tiab]
OR mix* up[tiab] OR "mix ups"[tiab] near* miss*[tiab] OR
oversight*[tiab] OR wrong*[tiab] OR mistake*[tiab] OR sub-
optimal practice[tiab] OR “Medical Errors”[mh] #3(#1
AND #2) #4“Medication Errors”[mh] #5drug inci-
dent*[tiab] OR medication incident*[tiab] OR medication
error*[tiab] OR drug* error*[tiab] #6(#3 OR #4 OR
#5) #7(lookalike[tiab] OR “look-alike*”[tiab] OR sound-
alike[tiab] OR sound-alike*[tiab] OR LASA[tiab] OR LASAs
[tiab] #8similarity[tiab] OR similar[ti] #9confus*
[tiab] #10((name*[tiab] OR title*[tiab]) AND (generic
[tiab] OR brand*[tiab] OR trade[tiab] OR proprietary[tiab]
OR commercial[tiab] OR international nonproprietary[tiab]
OR INN[tiab] OR INNs[tiab] OR BAN[tiab] OR BANs[tiab]
OR British approved[tiab] OR pharmacopoeial title*[tiab]
OR nomenclature*[tiab] OR packag*[tiab] OR label*
[tiab])) #11(colour[tiab] OR color[tiab] OR font[tiab] OR
fonts[tiab] OR typograph*[tiab] OR Tall Man[tiab] OR tall
man[tiab] OR lettering[tiab] OR upper case[tiab] OR lower
case[tiab] OR automated alert*[tiab] OR CPOE*[tiab] OR
computerized physician order entry[tiab] OR barcod*[tiab]
OR distract*[tiab] OR interrupt*[tiab]) #12(#7 OR #8 OR
#9 OR #10 OR #11) #13(#12 AND #6) #14animals
[mh] NOT humans[mh] #15(#13 NOT #14)
Web of Science search strategy
KEY: TS= Topic Search (Title, Abstract & Keywords); TI=
Title Only Search No Limits Applied Search run:
2016 01 26: RESULTS = 2,126 #1TS=(prescri* OR “drug
administ*” OR dispens* OR pharmacist* OR drug* OR medi-
cine* OR medication* OR pharmaceutical* OR
“pharmacotherapeutic agent*” OR “medicinal prod-
uct*”) #2TS=(error* OR “mix* up” OR “mix-up*” OR
“near* miss*” OR oversight* OR wrong* OR mistake* OR
“suboptimal practice” OR “medical error*”) #3(#1 AND
#2) #4TS=(“drug incident*” OR “medication incident*”
OR “medication error*” OR “drug error*”) #5(#4 OR
#3) #6TS= (lookalike* OR “look-alike*” OR soundalike*
OR “sound alike*” OR LASA OR LASAs OR "LA-SA" OR
"LA-SAs") #7TI= (similar) #8TS=(similarity OR simi-
larities OR confus*) #9(#6 OR #7 OR #8) #10TS=
(name* OR title*) #11TS=(generic OR brand* OR trade
OR proprietary OR commercial) #12TS=(“international
nonproprietary” OR “international non-proprietary” OR INN
OR INNs OR BAN OR BANs OR “British approved” OR
pharmacopoeial OR nomenclature OR Packag* OR
label*) #13(#10 AND (#11 OR #12) #14(TS=(colo*r
OR font OR fonts OR typograph* OR “tall man” OR Tall
Man OR lettering OR “lower case” OR “upper case” OR
capitali?ation OR “automated alert” OR CPOE OR
“computeri?ed physician order entry” OR barcod* OR dis-
tract* OR interrupt*) #15(#9 OR #13 OR #14) #16
(#15 AND #5) #17(Exclude: Letters, Editorials, News
Items, Notes, Item about an Individual, Book Chapter)
EMBASE search strategy (via OVID)
KEY: .ti. = Title field only; ti,ab. = Title & Abstract fields; / =
EMTREE index term No Limits Applied Search run:
2015 12 16: RESULTS = 3382 #1(prescri* or drug
administ* or dispens* or pharmacist* or drug* or medicine*
or medication*).ti,ab. #2(pharmaceutical* or
pharmacotherapeutic agent* or medicinal product*).ti,-
ab. #3drug administration/
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#4prescription #5drug/ #6drug therapy/ #7(#1
or #2 or #3 or #4 or #5 or #6) #8(error* or mix* up or
mix-up* or near* miss* or oversight* or wrong* or mistake*
or suboptimal practice).ti,ab. #9medical error/ or
error/ #10(#8 or #9) #11(#7 and #10) #12medi-
cation error/ #13(drug incident* or medication incident*
or medication error* or drug error*).ti,ab. #14(#11 or
#12 or #13) #15(lookalike* or look-alike* or soundalike*
or sound alike* or LASA or LASAs or LA-SA or LA-SAs).ti,-
ab. #16similar.ti. #17(similarity or similarities or
confus*).ti,ab. #18(#16 or #17) #19(name* or title*).
ti,ab. #20(generic or brand* or trade or proprietary or
commercial).ti,ab. #21generic drug/ #22(interna-
tional nonproprietary or international non-proprietary or
INN or INNs or BAN or BANs or British approved or phar-
macopoeial or nomenclature or Packag* or label*).ti,ab.
#23*drug labeling/ #24*drug packaging/ or *packag-
ing/ #25(#20 or #21 or #22 or #23 or #24)
Scopus search strategy
KEY: TITLE = Title field only; TITLE-ABS-KEY = Title ,
abstract & keyword fields No Limits Applied Search
run: 2015 12 16: RESULTS = 4168 SCOPUS - Rachel
Bryan – 2016 01 27 (Health Sciences and Social Sci-
ences & Humanities only) No other Limits applied
except for final exclusion as per #17 Search Run – 2016
02 04 RESULTS – 2344 Search Saved to Scopus by
CB #1TITLE-ABS-KEY(prescri* OR “drug administ*” OR
dispens* OR pharmacist* OR drug* OR medicine* OR medi-
cation* OR pharmaceutical* OR “pharmacotherapeutic
agent*” OR “medicinal product*”) #2TITLE-ABS-KEY
(error* OR “mix* up” OR “mix-up*” OR “near* miss*” OR
oversight* OR wrong* OR mistake* OR “suboptimal prac-
tice” OR “medical error*”) #3#1 AND #2 #4TITLE-
ABS-KEY(drug incident*” OR “medication incident*” OR
“medication error*” OR “drug error*”) #5#4 OR
#3 #6TITLE-ABS-KEY(lookalike* OR “look-alike*” OR
soundalike* OR “sound alike*” OR LASA OR LASAs OR "LA-
SA" OR "LA-SAs") #7TITLE(similar) #8TITLE-ABS-
KEY(similarity OR similarities OR confus*) #9#6 OR #7
OR #8 #10TITLE-ABS-KEY(name* OR title*)
#11TITLE-ABS-KEY(generic OR brand* OR trade OR propri-
etary OR commercial) #12TITLE-ABS-KEY(“international
nonproprietary” OR “international non-proprietary” OR INN
OR INNs OR BAN OR BANs OR “British approved” OR
pharmacopoeial OR nomenclature OR Packag* OR
label*) #13#10 AND (#11 OR #12) #14TITLE-ABS-
KEY(colo*r OR font OR fonts OR typograph* OR “tall man”
OR Tall Man OR lettering OR “lower case” OR “upper case”
OR capitali?ation OR “automated alert” OR CPOE OR
“computeri?ed physician order entry” OR barcod* OR dis-
tract* OR interrupt*) #15#9 OR #13 OR
#14 #16#15 AND #5 #17Exclude: Letters, Editorials,
Notes, Book Chapter, Books
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